MTX-474 for scleroderma, diffuse

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Dec 2025: Trial registered, NCT07287670
  2. 16 Apr 2026: Trial started, NCT07287670

The trials

NCT07287670: EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

State
Under way
Phase
Phase 2
People
85 planned
Started
16 Apr 2026
Primary completion
Dec 2028
Arms
MTX-474
Results
None posted
  1. 17 Dec 2025: Trial registered
  2. 16 Apr 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.